**Company Profile**

**Industry Sector:** Pharmaceuticals

**Company Overview:** COGNOSCI is developing and testing peptide compounds derived from the Apolipoprotein E (ApoE) for anti-inflammatory and neuroprotective activities. Pre-clinical studies with lead compounds COG112 and COG1410 showed promising results in animal models of Alzheimer’s disease, Multiple Sclerosis and Nerve Injury. We anticipate IND filings for these compounds in 1Q2010. The company funded pre-clinical research primarily through grant support from NIH and DOD. Cognosci is seeking financing and/or partnerships for Phase I and Phase II clinical trials. Cognosci has an experienced management team and a distinguished SAB with expertise in neuroscience and regulatory affairs.

**Target Market(s):** Our customers are pharmaceutical companies seeking treatments with novel mechanisms of action for Alzheimer’s Disease, Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury, Peripheral Nerve Crush, Peripheral Neuropathy and Cancer.

**Key Value Drivers**

**Technology:** Cognosci’s “COG” compounds protect neurons from the harmful effects of disease- and injury-associated inflammation. These COG compounds activate Protein Phosphatase 2A, thereby blocking protein kinase activities that are essential for the inflammatory response. COG compounds also stimulate neuronal repair and re-myelination in animal models. COG compounds administered subcutaneously readily cross the blood brain barrier and protect brain tissue in animal models of traumatic brain injury.

**Competitive Advantage:** Cognosci independently developed the COG peptide concept and has strong intellectual property protection. The company has been highly successful in securing federal grant funding and working with collaborators to advance pre-clinical research.

**Plan & Strategy:** We are aggressively conducting compound activity and safety testing in animals to prepare for filing IND applications in 2010. We intend to partner with a larger pharmaceutical company to conduct Phase 1 and Phase 2 clinical trials.

**Product Pipeline**

<table>
<thead>
<tr>
<th>Development Pipeline</th>
<th>Research &amp; Lead</th>
<th>IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s Disease</td>
<td>COG112</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Sclerosis</td>
<td>COG1410</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traumatic Brain Injury</td>
<td>COG112</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic Lymphocytic Leukemia</td>
<td>COG1410</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal Cord Injury</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

http://www.cognosci.com/pipeline.html#ms

**Management**

**Leadership:**

Michael P. Vitek, Ph.D.  CEO and Founder  
25 years of pharmaceutical experience in drug discovery and management of development projects

Dale Christensen, Ph.D.  Vice President of Research/Business Development  
Over 10 years of pharmaceutical, transactional and biological experience in drug discovery

Fengqiao Li, Ph.D.  Principal Scientist  
Over 20 years of scientific experience with molecular, cellular and animal models of human disease

**Scientific Advisory Board:**

Bruce Trapp, Ph.D., Chairman of Neurosciences, Cleveland Clinic
Daniel T. Laskowitz, M.D., Director of Translational Neurosciences, Duke
Paul T. O’Connor, M.D., Chief of Neurology, University of Toronto
Bruce K. Burnett, Ph.D., Director of Regulatory Affairs, Duke